Tremendous Potential For Fibromyalgia Pharmaceuticals In Europe

Main Category: Fibromyalgia
Article Date: 20 May 2008 - 3:00 PST

email to a friend   printer friendly   view / write opinions   rate article

With no available therapy for the treatment of fibromyalgia syndrome (FS), pharmaceutical companies have shown great interested in coming up with possible recommendations and therapies for treatment. Central nervous system (CNS) niche disorders have always been a major challenge and FS is no different. Some of the key products in late-stage clinical trials have shown considerable promise and offer high growth opportunities.

New analysis from Frost & Sullivan (http://www.pharma.frost.com), European Markets for Fibromyalgia Syndrome, finds that the market earned revenues of USD 73.4 million in 2007 and estimates this to reach USD 406.3 million in 2013.

"The increasing number of patients being diagnosed with CNS niche disorders, coupled with the lack of drugs to cater to them, has created tremendous scope for new blockbuster products," notes Frost & Sullivan Research Analyst Sriram V. "The absence of effective long-term treatment alternatives for neuropathic pain disorders such as FS has created a large pool of potential patients."

Current drugs used for CNS disorders have negative side effects, creating ample scope for the research and development of more effective alternatives with higher safety profiles.

CNS disorders feature a wide range of unrelated conditions with different aetiologies and epidemiologies. Despite an array of CNS drugs with good efficacy patterns, there is high demand for drugs with a lower incidence of extrapyramidal symptoms (EPS) and reduced side effects.

"The side effects associated with neuroleptics and antipsychotics include metabolic disturbances, weight gain and hyperprolactinaemia, which are very serious in nature," explains Sriram. "Poor tolerability leads to poor treatment compliance and the risk of relapse."

Developing orphan drugs in collaboration with technology start-ups or academic institutions offers specialty pharmaceutical companies little financial reward in the short term. However, over the longer term, it may enable them to access discovery and delivery technologies that would otherwise be prohibitively expensive but that could prove highly valuable to their future growth.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the European markets for fibromyalgia syndrome, then send an e-mail to Patrick Cairns, Corporate Communications, at pcairns_pr@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by e-mail.

European Markets for Fibromyalgia Syndrome is part of the Pharmaceutical and Clinical Diagnostics Growth Partnership Services Programme, which also includes research in the following markets: European CNS Therapeutics Markets, European Osteoarthritis Markets and U.S. Opioid and Non Opioid Pain Management Pharmaceuticals Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

http://www.frost.com